Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: James Perry who wrote (437)	9/17/1998 10:34:00 AM
From: Invest2Ride	Respond to of 1025

Thanks! That was very clear and remarkably concise given the complexity of the issues. I really appreciate the time you took to write it. Watching the price intently now. I'll be jumping very soon, I'm sure.

To: James Perry who wrote (437)	9/17/1998 11:59:00 AM
From: Skywatcher	Respond to of 1025

James...as usual a very good post with the top issues very clearly delineated for us...thanx chris

To: James Perry who wrote (437)	9/18/1998 12:20:00 AM
From: John Zwiener	Read Replies (1) \| Respond to of 1025

Hi James, just a few comments, Roche is placing over 1,000 instruments per quarter, twice as fast as the previous best seller of immunoassay instruments. The 60,000 per instrument is Igen's conservative estimate of the ELECTSYS average. I think this is low for good reasons, very low. Roche is claiming only 15,000 or so per instrument, but this can't be true because I doubt they would be profitable, and why would they continue to place instruments so fast. Also, 15,000 is impossible because the average immunoassay instrument does 6o,000, but Roche is placing them is bigger institutions first, plus even in small institutions, I think 60,000 is low. The total number of instruments as of May was minimum 6,000. It is Sept now. High through put should do a quarter of million per instrument. Agreements are with 5 companies, but some are for more than one instrument, so far. The 40 per share for Roche license buyout I believe may be minimum, but that could be close. But 60 is possible. As example of sensitivity of assay, the E. coli is 1,000 times more sensitive, with more specificity for the virulent isotypes of E.coli than the next best commercial test, and that last one is still under development. I think potential is higher.

To: James Perry who wrote (437)	9/18/1998 12:44:00 AM
From: John Zwiener	Respond to of 1025

James, regarding the press release on new test, This may well bring attention to the potential of Igen in drug discovery. I need more details, but this is the area where I think Igen has the biggest potential and advantage. The ability to measure the effects of the thousands of new compounds, and growing exponentially, on the basic cellular biology is what Igen is made for. I don't think this has been considered yet by the analysts who seem to have trouble understanding this company's potential. I doubt this news will have an immediate impact on price, but to me, it is what I have been waiting for, if details confirm initial impressions. Igen may end up in the middle of the biggest revolution in pharmacueticals and medicine . And Igen now says they want to discover their own compounds, and I bet they have some potentials in mind. Worth waiting to see what happens over the next couple of years .